Q4 2012 · —
Revenue$183.70M$183.70M +119.9% vs Q4 2011+4.7% vs Q3 2012
Net Income$200.55M$200.55M +435.2% vs Q4 2011+503.9% vs Q3 2012
EPS Diluted$3.28$3.28 +315.2% vs Q4 2011+496.4% vs Q3 2012
Gross Profit$156,179,000+102.6%
Operating Incomederived$67,378,000+78.9%
Operating Cash Flowderived$104,345,000+139.0%
Free Cash Flowderived$103,362,000+140.9%
Margins · derived
Gross margin85.0%−7.2 pt vs Q4 2011
Operating margin36.7%−8.4 pt vs Q4 2011
Net margin109.2%+64.3 pt vs Q4 2011
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q4 2012 | Q4 2011 | Q4 2010 |
|---|---|---|---|
| Revenue | $183.70M | $83.54M | $83.54M |
| Net Income | $200.55M | $37.47M | $37.47M |
| EPS Diluted | $3.28 | $0.79 | $0.79 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR